Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment

[Image: see text] Cancer immunotherapy can be augmented with toll-like receptor agonist (TLRa) adjuvants, which interact with immune cells to elicit potent immune activation. Despite their potential, use of many TLRa compounds has been limited clinically due to their extreme potency and lack of phar...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomacromolecules
Main Authors: Smith, Anton A. A., Gale, Emily C., Roth, Gillie A., Maikawa, Caitlin L., Correa, Santiago, Yu, Anthony C., Appel, Eric A.
Format: Artigo
Jezik:Inglês
Izdano: American Chemical Society 2020
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497526/
https://ncbi.nlm.nih.gov/pubmed/32816460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biomac.0c00812
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki